Detalles de la búsqueda
1.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34081848
2.
Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.
Int J Cancer
; 153(4): 803-814, 2023 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36971103
3.
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Br J Cancer
; 119(9): 1075-1085, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353045
4.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Br J Cancer
; 119(11): 1401-1409, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30353044
5.
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet Oncol
; 17(11): 1579-1589, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27617661
6.
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
Cancer
; 122(12): 1844-52, 2016 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27062051
7.
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
Br J Cancer
; 115(11): 1313-1320, 2016 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-27824811
8.
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
Oncologist
; 21(2): 172-7, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26786262
9.
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Lancet Oncol
; 15(8): 852-61, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24882434
10.
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
J Clin Oncol
; 42(1): 47-58, 2024 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37870536
11.
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
J Clin Oncol
; 42(11): 1288-1300, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38301187
12.
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Eur J Cancer
; 184: 39-47, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36893711
13.
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group.
Clin Cancer Res
; 27(9): 2416-2423, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33563636
14.
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
Clin Pharmacokinet
; 58(9): 1165-1174, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30877569
15.
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Oncotarget
; 8(27): 43653-43661, 2017 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28525389
16.
Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
Cancer Chemother Pharmacol
; 78(4): 775-84, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27553432
17.
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
Clin Ther
; 38(10): 2286-2299, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27745744
18.
Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.
Adv Ther
; 32(6): 510-22, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26048134
19.
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
J Clin Oncol
; 33(3): 244-50, 2015 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25366685
20.
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Cancer Chemother Pharmacol
; 76(4): 723-9, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26242220